Moderna’s COVID-19 vaccine brought in more than $4 billion in second-quarter sales, helping to push the vaccine developer into a profit.
The company also said Thursday an analysis showed that its vaccine remains 93% effective as much as six months after the second dose.
Moderna’s announcement comes after pharmaceutical giant Pfizer Inc. said its COVID-19 vaccine remained effective months after the second dose and had become a top seller. It brought in nearly half the company’s revenue — $7.84 billion from direct sales and revenue split with its partner, Germany’s BioNTech.
The COVID-19 vaccine is Moderna’s only commercially approved product. It also is developing several vaccines that aim to guard against the flu, Zika and HIV among other viruses. Those are all in early stages of clinical testing, according to its website.
The company also is testing a potential booster shot for the COVID-19 vaccine.
Overall, Moderna earned $2.78 billion in the second quarter, compared to a loss of $117,000 last year, before its vaccine received emergency use authorization in the U.S. and other countries to fight the global pandemic.
The company brought in $4.35 billion in total revenue, thanks to the vaccine and some grants. Earnings per share totaled $6.46.
The results topped Wall Street expectations. Analysts surveyed by Zacks Investment Research expected, on average, earnings of $6.01 per share on $4.29 billion in revenue.
Moderna’s COVID-19 vaccine has received emergency authorization for use in more than 50 countries.
Cambridge, Massachusetts-based Moderna Inc. also said Thursday that it completed enrollment in an early-stage study of its next-generation COVID-19 vaccine, which could be easier to store and distribute. The company also said it will explore a combination vaccine that aims to offer protection against the flu, COVID-19 and other viruses.
Company shares fell 4% to $402 in premarket trading Thursday. The stock price has quadrupled since the end of 2020.
Elements of this story were generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MRNA at https://www.zacks.com/ap/MRNA
Regulators authorized AstraZeneca’s coronavirus vaccine for use in adults throughout the European Union on Friday, amid criticism the bloc is not moving fast enough to vaccinate its population.
WASHINGTON (AP) — A former FBI lawyer was sentenced to probation for altering an email that the Justice Department relied on during its surveillance of an aide to President Donald Trump during the Russia investigation.
MADISON, Wis. (AP) — Democratic Gov. Tony Evers lashed out Friday at rival Republicans who tried to repeal his statewide mask mandate, saying killing the order would be a ridiculous move comparable to abolishing speed limits.
COLUMBIA, S.C. (AP) — As some conservatives in South Carolina celebrated getting a bill that would ban almost all abortions in the state past a legislative barrier and likely becoming law, they said they are not finished trying to end all abortions.
A Moscow court on Friday put the brother and several allies of Russian opposition leader Alexei Navalny under house arrest for two months as authorities sought to stymie more protests over the jailing of the top Kremlin foe.